Menu Search
Equities

Delta-Fly Pharma Inc

4598:TYO

Delta-Fly Pharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)638.00
  • Today's Change28.00 / 4.59%
  • Shares traded766.10k
  • 1 Year change-61.22%
  • Beta0.2609
Data delayed at least 20 minutes, as of Nov 08 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Delta-Fly Pharma Inc's net income fell 7.57% from a loss of 1.33bn to a larger loss of 1.43bn despite flat revenues.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-204.19%
Return on equity-226.67%
Return on investment-226.67%
More ▼

Cash flow in JPYView more

In 2024, Delta-Fly Pharma Inc increased its cash reserves by 67.83%, or 572.72m. Cash Flow from Financing totalled 1.85bn or -- of revenues. In addition the company used 1.28bn for operations while cash from investing totalled 207.00k.
Cash flow per share-216.21
Price/Cash flow per share--
Book value per share89.00
Tangible book value per share89.00
More ▼

Balance sheet in JPYView more

Delta-Fly Pharma Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio8.26
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.